Cohance Lifesciences Limited — Q3 FY26
Cohance Lifesciences reported a weak Q3 FY26 with consolidated revenue declining 19.5% YoY to ₹545 crore, impacted by destocking in two large commercial products (~₹260 crore im...
bearish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
54%Questions answered3Evaded / deflected12Questions auditedContradictedNumbers vs filing
Partial answer
High priority
Retaining $1B FY30 target despite FY26 guidance cut?
Asked by L of Forum Parik, BB Capital Markets
Affirmed target but admitted timing shift without specifics.
no revised timeline givenqualitative commitment only
Read the exchange
Question
since we have lowered the revenue guidance for FY26 to mid to early to mid double digit. So my first question is how are we retaining our $1 billion USD sales target for FY30?
Himu (CEO)
Yes, we are committed to our billion dollar guidelines. Timing might shift slightly because of the challenges we have seen this year, but overall management is fully committed to the long-term guidelines that we have.
Answered
High priority
Can we anticipate growth in FY27?
Asked by L of Forum Parik, BB Capital Markets
Simple yes/no answered affirmatively.
Read the exchange
Question
do we can we anticipate growth in FI27 or it's still far away?
Himu (CEO)
Yes, we are fully working for growth in FI27.
Partial answer
High priority
API growth outlook for FY27?
Asked by L of Forum Parik, BB Capital Markets
Affirmed growth but gave no numbers or specifics.
no quantificationvague reference to offshoots
Read the exchange
Question
API contributes almost 50% of our total sales. So how should we look at it? Can we anticipate growth in FI27?
Himu (CEO)
API as well is looking at growth in the business. The growth that we are reflecting in FI27 is a function of what offshoots we are seeing as of now.
Declined
High priority
Quantify FY27 growth rate?
Asked by L of Forum Parik, BB Capital Markets
Explicitly refused to provide quantitative guidance.
deferred to future quartersno number given
Read the exchange
Question
Would you like to quantify what's the growth we are looking at for FY27 on a blended level?
Himu (CEO)
We are still in the midst of iron tightening our budget assumptions... I would request you and the community to be patient with us and give us some more time... in one or two quarters.
Partial answer
Medium priority
Niche technology contribution this quarter?
Asked by L of Forum Parik, BB Capital Markets
Provided 9-month aggregate but avoided quarterly breakdown.
gave 9-month figure not quarterlysaid lumpy business
Read the exchange
Question
Are we calling out on the niche technology contribution for the quarter like contribution from ADC and oligo for this quarter?
Himu (CEO)
We started calling out the niche technology percentage... we have indeed called up for this quarter... for 9 months it has been around 15% and that's what I would urge the community to look at.
Evasive
High priority
Is 55cr impact from Nacharam peak or more to come?
Asked by Alman Das, JP Morgan
Did not confirm if 55cr is peak; only described ongoing remediation.
no clear peak vs more impactqualitative only
Read the exchange
Question
it had an impact of around 55 crores. So is this a peak of the negative impact that we see from this facility or should we bake in some more impact?
Gunj (Operations Head)
There will be some slowdowns for sure because there will be some delays while we implement the remediation activities. Our revenues or our production or dispatches and production for the non-US market would continue while the US will take gradual resumption.
Answered
Medium priority
Clarify 2% figure: consolidated or US revenue?
Asked by Alman Das, JP Morgan
Provided clear clarification.
Read the exchange
Question
So is it 2% of the console sales or 2% of the US revenues per se?
Himu (CEO)
it is less than 2% of the consolidated sales.
Answered
High priority
Conversion rate and timeline for RFQs?
Asked by Alman Das, JP Morgan
Provided specific conversion rate and qualitative trend.
Read the exchange
Question
what's the conversion rate on this RFQS... if you have 100 RFQS... how many actually converts to a commercial molecule and what's the typical timeline?
Yan (Business Head)
normally the percentage win is around 20%. That's what you can expect... the funnel that we have today is significantly better than what we had one quarter ago.
Evasive
Medium priority
End market size for four commercializing molecules?
Asked by Alman Das, JP Morgan
Gave volume example but refused to quantify in value terms.
no dollar value givensaid clients may not know
Read the exchange
Question
these four molecules which are going commercial next year what could be the end market size that we could guess?
Yan (Business Head)
it really depends on the application... one application is ADHD I mean the volume could be almost triple digit metric tons... for oncology it's different... very difficult to quantify.
Partial answer
Medium priority
Is 55cr impact from Nacharam plant sales going to zero?
Asked by Kunal Damisha, McQuary
Corrected assumption but did not give current run-rate.
did not confirm zero salesblended impact
Read the exchange
Question
the sale of from that plant has gone to zero now in the 9 month FY26.
Himu (CEO)
What you have seen 55 is an effect of both the loss of supplies to US market as well as to non-US market during the period of the shutdown. So it's a mix of both. Again to repeat we have opened the plant for non-US market.
Answered
High priority
Destocking impact of 260cr from two products correct?
Asked by Kunal Damisha, McQuary
Confirmed the analyst's calculation.
Read the exchange
Question
the 9 month FI26 or 9 month FI25 number for those two products minus 9 month FI26 number for those two products is 260 K. That's the impact. That's the decline.
Himu (CEO)
Yes, that is broadly correct.
Partial answer
High priority
Margin trajectory: moving to lower level?
Asked by Shamsini Vasan, Goldman Facts
Affirmed long-term target but avoided near-term margin level.
no quantitative margin rangedeferred to mid-term
Read the exchange
Question
are we now moving to a slightly lower trajectory of margins... just want to understand the margin walk there.
Himu (CEO)
we are not sensing that there is a change in the margin profile from a mid-term perspective but yes short-term is impacted... we remain close to the guidance that we have said that we will reach to the margin of 30 plus.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Margin target of 30% plus | 30% | 15.6% | Overstated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.